Tumor angiogenesis is regulated by an intricate balance of various growth factors, of which VEGF is considered to be the most potent and critical. [3] [4] [5] EGFR/ErbB-2 receptor stimulation increases tumor cell expression of VEGF; blocking EGFR and/or ErbB-2 function by using monoclonal antibodies or small molecule TK inhibitors (TKIs) decreases tumor cell production of proangiogenic molecules, such as VEGF, and inhibits tumor-associated angiogenesis. 3, [6] [7] [8] [9] [10] Several agents designed to inhibit EGFR (eg, gefitinib, erlotinib, cetuximab, panitumumab) or VEGF/VEGFR (eg, sorafenib, sunitinib, bevacizumab, ranibizumab) are commercially available and/or under investigation. 10 However, because tumor cell proliferation and angiogenesis are dependent on numerous complex biochemical pathways, targeting a single step in a single pathway is unlikely to provide optimal therapeutic outcomes, and may even cause tumor cells to divert to compensatory pathways for survival. Combination therapy regimens designed to attack multiple oncogenic targets are likely more effective. The results of several preclinical and clinical trials have demonstrated additive/synergistic antitumor activity with concomitant administration of anti-EGFR and anti-VEGF therapies in some cancer models. 11, 12 AEE788, an orally active, reversible TKI, selectively inhibits multiple EGFR and VEGF pathway targets in vitro, including 2 ErbB receptors: EGFR/ErbB-1 (A431 cells; IC 50 : .011 µM) and HER-2/neu (ErbB-2) (BT-474 cells; IC 50 : .22 µM); and, 1 VEGF receptor: VEGFR-2/KDR (Chinese hamster ovary cells; IC 50 : .96 µM). 6 The assessment of target inhibition by molecularly targeted agents, also known as pharmacodynamic studies, has been increasingly incorporated in early clinical trials to define degree of target inhibition and downstream effects and, in some cases, to select the preferred dose and schedule of a given compound. [13] [14] [15] However, pharmacokinetic and pharmacodynamics studies have rarely been used to determine whether a drug entity is suitable for further clinical development. Early clinical development criteria for AEE788 were to not only evaluate the safety and efficacy of AEE788, but to also demonstrate inhibition of EGFR and VEGFR-2 using dose-effect modeling in cancer patients.
Here within, we report the results of this first-in-human, phase 1, multicenter, doseescalation study evaluating oral AEE788 in patients with advanced cancer and describe how the integration of phase I PK, PD, biomarker, and safety data helped facilitate early decisions regarding the clinical development of this drug.
Research. 
Patients and Methods

Patient Population
Patients ≥ 18 years old with histologically-confirmed, advanced solid tumors whose disease progressed despite standard therapy or for whom no standard therapy existed were eligible for enrollment. Main inclusion criteria included measurable or nonmeasurable lesion(s) as defined by the modified Response Evaluation Criteria in Solid Tumor (mRECIST) criteria; age ≥18 years; life expectancy ≥12 weeks; Karnofsky Performance Status (KPS) of ≥ 70; and adequate bone marrow, hepatic, and renal function.
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Patients were excluded if they had certain preexisting or concomitant malignancies or other severe and/or uncontrolled medical conditions or received prior VEGF or VEGFR or EGFR/ErbB-2 targeted therapies. Use of chemotherapy, investigational drugs, or wide-field radiation therapy had to be discontinued ≥ 4 weeks, and immunotherapy, major surgery or hematopoietic colony-stimulating factors discontinued ≥ 2 weeks before study entry. All patients gave informed consent, and approval was obtained from the ethics committees at the participating institutions and regulatory authorities. The study followed the Declaration of Helsinki and good clinical practice guidelines.
Methods
Dose Escalation
Patients received once daily, continuous dosing AEE788 in 28-day cycles. The starting dose of 25 mg was selected based on 4-week chronic dosing toxicology studies performed in rats (1/10 th of the non-lethal dose) and monkeys. Using a modified Fibonacci design, doses were escalated in increments of 100%, 67%, 50%, 40%, and 33% of the previous dose until dose limiting toxicities (DLTs) were reached. A DLT was defined as an adverse event (AE) or abnormal laboratory value assessed as unrelated to disease progression, concurrent illness, or concomitant medication that occurred during the 28 days following the first dose of AEE788 in cycle 1 and met predefined criteria (grade ≥ 3 hematologic, hepatic, cardiac, or other AE; grade ≥ 2 renal AE or hypertension; grade > 1 neurologic AE; and/or skin AE requiring AEE788 interruption longer than 7 days). The maximum tolerated dose (MTD) was determined based on a "3+3" algorithm using the DLT data from cycle 1. After the completion of the doseescalation phase, a dose expansion phase further evaluated the safety and efficacy of AEE788; the doses evaluated in the dose-expansion phase were chosen based on the safety and clinical data obtained from the dose-escalation phase.
Study Endpoints
The primary study endpoint was to define MTD based on the DLTs of AEE788 in patients with advanced solid tumors. Secondary endpoints included 1) determining the safety and tolerability of AEE788; 2) characterizing the single-and repeated-dose PK profile of AEE788 and its primary metabolite, AQM674; 3) identifying potential biomarkers indicative of target inhibition and efficacy; and 4) evaluating preliminary antitumor activity of AEE788.
Specimen Collection
Immunohistochemistry analysis of skin and tumor biopsies
Tissue biomarker studies were used to determine whether AEE788 inhibits EGFR and IHC analysis of EGFR-related ligands, including EGF, TGF-α, heregulin, and neuregulin were also performed in tumor biopsies.
Total forms of the phosphorylated protein biomarkers were also assayed as controls of stability of the respective proteins. Expression of biomarkers was calculated in a blind fashion using an H-score, as previously described. 17, 18 (Supplementary Table 1 
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Maximum inhibition (E max ) of biomarkers was achieved when all target receptors were occupied (efficacy and or intrinsic efficacy equal to 0); the serum drug concentration for 50% inhibition (IC 50 ) and 80% inhibition (IC 80 ) were determined. Modeling procedures were carried out by fitting a mathematical inhibitory E max model to observed concentration-effect data with SAS software and model parameters (E max , IC 50 ) estimated by nonlinear, least squares regression.
Statistical Analyses of PD markers
An exploratory analysis was performed to identify target biomarkers that correlated with progression-free survival (PFS); prognostic patterns were characterized for biomarker pairs (ie, baseline only, post-baseline only, percentage change from baseline). Because these analyses were completed for exploratory and hypothesis-generating purposes only, no corrections for multiplicity were performed. All biomarker data (both pre-and post-treatment) were standardized by subtracting the pre-treatment mean and dividing by the pre-treatment standard deviation (SD) (linear or log scale) making the pre- treatment SD the unit of measurement for all biomarker data. Cox proportional hazards models were applied to these standardized biomarker pairs, adjusting for AEE788 dose; statistical significance (P<0.05) was determined using likelihood ratio tests. To facilitate clinical interpretation of the findings, Kaplan-Meier estimates of PFS were generated for relevant biomarker subgroups formed by dichotomizing biomarkers at the median.
Statistical analyses were performed using SAS Version 8.2 and S-plus version 6.2.
Results
Patients
Between July 2003 through August 2005, 111 patients were enrolled. Three to 6 evaluable patients were enrolled to each dose levels: 25, 50, 100, 150, 225, 300, 400, 450, 500, and 550 mg. Baseline patient characteristics are summarized in Table 1 .
DLTs were reported in 1 of 6, 2 of 6, and 2 of 6 MTD evaluable patients in the 450 mg (skin rash), 500 mg (diarrhea) and 550 mg (diarrhea) dose groups, respectively. The MTD was therefore defined as 450 mg. The most frequently reported drug-related AEs in all groups (reported in > 30% of patients) were diarrhea, nausea, anorexia, rash, fatigue, and vomiting (Supplementary Table 2 Approximately 20% of patients initially receiving 225 mg to 300 mg experienced grade 3 AST/ALT; therefore, additional 250 mg cohorts were enrolled in the dose-expansion phase to further evaluate AEE788 safety. Likewise, because the MTD was found to be 450 mg and 1 patient experienced a partial response at 400 mg, additional 400 mg cohorts were evaluated in the dose-expansion phase to further evaluate AEE788 safety and clinical activity.
Pharmacokinetics
Serum concentrations of AEE788 and AQM674 were highly variable. The mean coefficients of variation (SD/mean) for C max and AUC 0-24 were on average 70%. C max for AEE788 and AQM674 was achieved at 2 to 7 and 3 to 8 hours post-dose, respectively, and fluctuated 2-fold (C max /C min ratio) during the 24-hour dosing interval (Supplementary 
Serum concentrations of AEE788 and AQM674 increased with increasing dose and dose duration (number of doses) (Fig 2) . AEE788 exposure (a factor of both drug dose and elimination) increased overproportionately with the dose while AQM674 exposure increased proportionately with the dose. After 15 and 28 days of dosing, parent drug and metabolite exposure were 2-to 8-and 2-to 5-fold higher, respectively, than the first dose exposure. Although the apparent terminal disposition (first order) rate constant could not be accurately estimated, the observed accumulation did not appear to be caused by a decrease in the elimination process. Exposure of parent drug and metabolite after 15 and 28 days of dosing were similar (except for the 25 mg dose), suggesting that steady state is reached on or before day 15.
AQM674 serum concentrations reflect relative changes to the parent drug, suggesting rapid metabolite formation with elimination equal to or faster than the parent drug. The ratio of metabolite to parent drug ranged from 0.2 to 2 and declined with dose and dose duration to a range of 0.3 to 0.4 (225-400 mg), an indication that metabolite formation pathway is saturable. Exposure-demographic (age, weight, body surface area, gender) relationships were explored, but not observed.
Pharmacodynamics
Cycle 1 day 28 (C1D28) AEE788 and AQM674 exposure in serum and corresponding biomarker response data in skin and tumor tissue was available for 46 to 53 and 10 to 13 patients, respectively, depending on the tissue and biomarker (Supplementary Table   Research. on In tumor, a significant inhibition of EGFR activation was demonstrated after AEE788 treatment (P=0.001), but no downstream effects were observed. Supplementary Figure   1 shows the pre-and post-treatment IHC results for p-MAPK and Ki67 in tumor, basal skin, and vascular granulation tissues, p-EGFR in tumor and basal skin tissues, and pAkt in tumor tissue in two selected patients treated at 25 and 550 mg dose levels.
The percentage inhibition in skin EGFR phosphorylation and Ki67 (Fig 3) and tumor p-EGFR and p-MAPK (Fig 3) levels increased with increasing drug dose and serum concentration of both AEE788 and AQM674. Inhibitory E max model fits of the effectsconcentration data, however, showed large variability as demonstrated by the wide 95% confidence intervals around model predicted (fitted) E max and IC 50 values (see Table 2 ). Conversely, inhibition of p-VEGFR-2 and cyclin D1 was not observed in tumor tissue, most likely because serum concentrations necessary to inhibit these markers were higher than serum concentrations achieved with the MTD (ie, toxicity occurred before concentrations required to inhibit these biomarkers was achieved). In terms of effects of AEE7888 on vasculature, no effect was seen on p-MAPK and Ki67 levels in skin vascular granulation tissue at doses below MTD; inhibition of vasculature p-MAPK and Ki67 was observed at doses > 400 mg. Table 2 summarizes the estimated E max model parameters for selected biomarkers in skin and tumor tissue.
Exploratory Statistical Analysis of Biomarker Data
Tumor Biomarkers
Because of the limited number of patients in whom fully evaluable paired tumor samples were available (n=24), tumor biomarker analyses were exploratory only. The Ki67 biomarker was identified as a potential predictive factor for PFS (likelihood ratio chisquare =16.999; 2 degrees of freedom [DF]; P=0.0002) ( Table 2 summarizes the Cox proportional hazard model estimates for the Ki67 biomarker pairs). In particular, the relative hazard for PFS depends strongly on the post-treatment Ki67 tumor value and is virtually independent of the baseline Ki67 tumor value. Interestingly, the percentage change from baseline in Ki67 expression does not appear to be meaningful in terms of prognosis, whereas the C1D28 Ki67 H-score appears to contain essentially all prognostic information. Consequently, a patient with a higher C1D28 Ki67 value has a higher risk of disease progression after C1D28 relative to the patient with the smaller C1D28 Ki67 value; a risk that is independent of baseline value. For example, a KaplanMeier plot depicts the PFS of patients with a C1D28 Ki67 value at the median value or less (≤ 30) verses those with a C1D28 Ki67 value greater than the median (> 30) (Fig   4) . A strong association between the baseline Ki67 value in tumor tissue and the C1D28 Ki67 value was also observed (n=24; Spearman correlation=0.6399; P=0.0008).
Basal Skin Biomarkers
AEE788 dosing was a significant prognostic factor for PFS in the subgroup of patients from whom basal skin samples were obtained. The log p-STAT3 biomarker pair was identified as a potential predictive factor for AEE788 treatment (likelihood ratio chisquare =6.705; 2 degrees of freedom; P=0.035) in this subgroup. Table 2 summarizes the Cox proportional hazard model estimates for the log p-STAT3 biomarker pair.
Higher baseline log p-STAT3 levels in basal skin tissue appears to be a potential adverse predictive factor for PFS in patients treated with AEE788. For example, the PFS rates of patients with a baseline basal skin p-STAT3 value at the median value or less (≤ 10) verses those greater than the median value (>10) are depicted in the Kaplan-Meier plot in Fig 4. 
Discussion
Validated methods to identify optimal dose-response relationships, clinically monitor drug activity, predict therapy outcome, or identify patients and/or tumors most likely to respond to anti-VEGF and anti-EGFR therapies are lacking. Although others have suggested that biomarker analyses in early drug development lead only to added cost and erroneous decision making, we found biomarker data to be essential to our decision to terminate further development of AEE788 beyond phase I trials. 23 Our approach was to determine the relationship of AEE788 PK and PD using the E max model and to couple the results with biomarker, efficacy, and safety data to facilitate real-time decisions regarding the clinical development of AEE788.
Although variability in drug exposure and biochemical responses were observed, the PD profiles of EGFR-pathway abrogation in skin and tumor can be considered similar (E max and IC 50 values in the same range), suggesting that EGFR inhibition in skin tissue may be a useful surrogate for EGFR inhibition in tumor tissue. A dose-response curve was used to identify AEE788 doses (150-225 mg po daily) that corresponded with near maximum inhibition (80%) of p-EGFR in skin and tumor providing consideration of pharmacologic effect of AEE788 for dose escalation. Furthermore, these dose-response curves helped identify AEE788 doses associated with the greatest inhibition of certain biochemical pathways relative to safety and efficacy findings at the same dose. In preclinical studies, AEE788 was found to inhibit EGFR and VEGFR-2. 6 Although the effects of EGFR and VEGFR pathway biomarkers in skin and tumor tissue correlated well with serum concentrations of both AEE788 and AQM674, when the E max model was applied AEE788 was found to only inhibit activation of EGFR, but not VEGFR-2 in skin and tumor tissue at serum concentrations at or below the MTD (450 mg).
Concentrations to achieve near maximum (80%) p-EGFR inhibition occurred between 0.05 and 0.13 µM, which corresponded with an AEE788 dose of 150 mg to 225 mg daily. IC 50 values of the functional downstream markers p-MAPK (0.02 µM) and Ki67 (0.0076 µM) in skin were similar the IC 50 for p-EGFR, suggesting the effects are likely driven by p-EGFR inhibition. At doses achievable in this clinical trial, AEE788 did not, however, inhibit VEGFR-2 in tumor tissue as was hypothesized. Further supporting these findings was the lack of MAPK and Ki67 inhibition in endothelial cells from the skin. Moreover, a large variability in serum AEE788/AQM674 exposure and observed change in biomarker expression was observed, which was likely caused by the small sample size of tumor tissue and/or that most tumor tissue samples came from patients treated at doses less than the MTD. Nevertheless, modeling the PK/PD data made it apparent that AEE788 did not meet the predefined criteria for further clinical development. Based on our findings it was concluded that AEE788 would not be able to provide optimal VEGFR inhibition at tolerable doses and, therefore, would provide no additional benefit from currently available EGFR inhibitors.
Although the exploratory statistical biomarker analysis was not a primary outcome of this study, the analysis was conducted to identify tumor and/or skin tissue biomarkers potentially predictive for PFS for further evaluation in future clinical trials. In this analysis, post-treatment tumor tissue Ki67 and basal skin pSTAT3 levels were found to be significant predictors of PFS. Patients with C1D28 Ki67 (biomarker indicative of cellular proliferation) levels less than the median level observed for the study population experienced a longer PFS. Whether these findings were related to AEE788's effect on tumor cell proliferation or suggest that slowly proliferating tumors respond to AEE788 more than rapidly proliferating tumors is not known; however, the existence of a correlation between Day 28 Ki67 levels and PFS despite baseline Ki67 levels suggests a direct effect of AEE788 on tumor cell proliferation. The extrapolation of these observations to other populations or settings is questionable; the tumor tissue dataset was small and obtained from patients treated at lower doses (ie, < 400 mg) for shorter durations.
Although the association between basal skin p-STAT3 level changes and PFS was somewhat weaker, p-STAT3 appears to be a tumor progression marker and was upregulated by AEE788 in basal skin and higher baseline levels were associated with shorter PFS times. Baselga and colleagues and Vanhoefer and colleagues reported similar findings with other EGFR inhibitors, gefitinib and EMD 72000, respectively. 17, 18 These findings suggest that STAT3 may be a valuable surrogate marker for identifying tumors or patients most likely to benefit from anti-EGFR therapy and may be associated with anti-EGFR therapy resistance development; however, further study is needed.
Conclusion
According to our PD model, which integrated serum exposure of AEE788 and AQM674
and PD data to determine the effects of AEE788 on various targets in the EGFR and VEGF pathways, AEE788 inhibits pEGFR, but not pVEGFR-2 at doses below the MTD.
These findings suggest that AEE788, administered at doses at or below the MTD, 
